These parameters most likely reflect concerns based on the published experience with JAKinibs in other scenarios, such as myelofibrosis, arthritis, and graft-versus-host disease (GVHD), as well as STAT1 GOF cases [8, 27, 28], FDA and EMA recommendations [19, 20]. The gene discussed is STAT1; the disease is myelofibrosis.